COVID-19 Respiratory Outcomes Registry
Post COVID-19 Hypoxemic Respiratory Failure Residual Pathophysiologic Outcomes
Sponsor: Boehringer Ingelheim
This observational or N/A phase trial investigates Covid19 and is currently completed. Boehringer Ingelheim leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Aug 2023 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Mar 2023 — Aug 2023 [monthly]
Active Not Recruiting
▶ Show 3 earlier versions
-
Nov 2022 — Mar 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Nov 2022 [monthly]
Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Recruiting
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .